日博集团

LANG
中
EN
R&D & INNOVATION
R & D strategy
Develop innovative and generic drugs simultaneously
We focus on R&D of drugs for chronic diseases such as cardio-cerebral vascular and metabolic diseases to establish the R&D system of high-end generic drugs and innovative drugs combination.
Internal Improvement and External Introduction
We have transformed our R&D model from fully independent to cooperate with external R&D institutions, and have introduced advanced technologies and teams globally to establish multiple platforms, lower the risks and improve the efficiency.
We cooperated with Kunming Institute of Zoology, CAS to establish Yunnan CAS Longjin Biotechnology Co., Ltd. which serves as the polypeptide innovative drugs R&D platform.
An external investment partner was introduced to establish Jiangsu Longjin Careyou Biomedical Co., Ltd. which serves the high-end generic drug development platform.
Longjin Fantian Biotechnology Co., Ltd. was established to serve as the investment hatch platform for seeking global excellent project resources for the company and introducing external scientific research institutions and fund for project hatching.
We maintain long-term friendly partnership with well-known research institutions such as Harvard Medical School, The Institute of Medicinal Plant Development, CAMS and Institute of Materia Medica Chinese Academy of Medical Science.
R & D philosophy
In line with the pure, truth-seeking, clinical demand-oriented research and development concept, we are committed to rapidly developing high-quality drugs to improve the living comfort of patients with chronic diseases.
R&D Capability
The R&D capability will become the long-term competitiveness and driving force of development. Longjin continuously increases the R&D investment. Our R&D investment increases at an annual rate of greater than 40% in recent three years and accounts for 7% of sales income, greatly supporting our strategic transformation and sustainable development.
Longjin has a R&D team composed of 30 members, including 1 member with the doctoral degree, 13 members with the master degree, 12 members with bachelor degree, 4 members with other education background; 1 member with the senior title, 6 members with the deputy senior title, 12 members with medium title, 11 members with other titles; 2 foreign employees. We have established R&D institutions in Kunming and Suzhou successfully, municipal, provincial corporate technical centers, 1 municipal post-doctoral scientific research support workstation and national “major new drugs innovation and manufacturing” special hatching base.
Meanwhile, based on the R&D strategy , we strengthen the R&D team construction, conduct self-improvement, strengthen independent innovation capability, and introducing the global advanced technologies and team to improve our drugs development capability;
Over the years, we have successively undertaken 2 special projects of “major new drugs innovation and manufacturing”, 1 project of national key R&D planning program, 1 national traditional Chinese medicine standardization project and multiple projects of municipal and provincial science and technology program, have applied for more than 30 invention patents (17 invention patents licensed), completed the medical research on the innovative drug ZKLJ02 for curing cerebral arterial thrombosis and now we are at the pre-clinical pharmacology and toxicology stage for such innovative drug. Our R&D team is composed of many talents and has the strong R&D capability.
Endless Innovation
R & D and innovation are closely intertwined, and the nature of the pharmaceutical industry requires companies to constantly engage in technological innovation or business model innovation in order to improve production efficiency through. One of the company’s strengths is using emerging technologies to engage in explorative innovation. From the construction and commissioning of automated production lines, to the comprehensive application of intelligent manufacturing systems, to the control of known impurities at the micro scale, to conducting quality control across the entire industrial chain, to the infinite applications of new materials, to the introduction of new production techniques, all forms of innovations revolve around the reliability and efficiency of product manufacture, while also reducing production costs.
R & D partnerships
互联网药品信息效劳允许证:（滇）－非谋划性－2020－0014
滇ICP备13000870号-1 滇公网安备 53019002000234号
     technical support：AYKJ

微信挚友

新浪微博

腾讯微博

QQ空间

豆瓣网

QQ挚友

作废
【网站地图】【sitemap】